PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.00M | 5.31M | 6.11M | 5.86M | 5.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.41M | 5.71M | 6.52M | 6.26M | 5.94M |
| Operating Income | -5.41M | -5.71M | -6.52M | -6.26M | -5.94M |
| Income Before Tax | 22.68M | 26.94M | 333.80K | -1.14M | -1.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.68 | 26.94 | 0.33 | -1.14 | -1.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.68M | 26.94M | 333.80K | -1.14M | -1.28M |
| EBIT | -5.41M | -5.71M | -6.52M | -6.26M | -5.94M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.27 | 1.40 | -1.75 | -1.46 | -0.84 |
| Normalized Basic EPS | 0.54 | 0.51 | 0.25 | -0.01 | 0.01 |
| EPS Diluted | 0.83 | 0.96 | -1.75 | -1.46 | -0.84 |
| Normalized Diluted EPS | 0.54 | 0.51 | 0.25 | -0.01 | 0.01 |
| Average Basic Shares Outstanding | 32.46M | 33.59M | 38.32M | 47.78M | 58.16M |
| Average Diluted Shares Outstanding | 32.46M | 33.59M | 38.32M | 47.78M | 58.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
